For research use only. Not for therapeutic Use.
Foxy-5 TFA, a WNT5A agonist, is a mimicking peptide of WNT5A which is a non-canonical member of the Wnt family. Foxy-5 TFA triggers cytosolic free calcium signaling without affecting β-catenin activation and it impairs the migration and invasion of epithelial cancer cells. Foxy-5 TFA effectively reduces the metastatic spread of WNT5A-low prostate cancer cells in an orthotopic mouse model[1][2][3].
Foxy-5 TFA (100 μM, 24 h) inhibits the invasion of tumor cells in DU145 cells[3].
Foxy-5 TFA (2 mg/kg intraperitoneally injected 9 times a day for 7-23 days) reduces the number of colon cancer stem cells in a mouse model of human colon cancer xenotransplantation[2].
Foxy-5 TFA (2 mg/kg, intraperitoneal injection, once a day, for 3-9 weeks) significantly reduces the early metastasis and spread of WNT5A low DU145 prostate cancer cells in a mouse model of prostate cancer xenotransplantation[3].
| Catalog Number | I046149 |
| Synonyms | (2S)-2-[[(2S)-4-carboxy-2-[[(2R)-2-[[2-[[(2S)-3-carboxy-2-[[(2S)-2-formamido-4-methylsulfanylbutanoyl]amino]propanoyl]amino]acetyl]amino]-3-sulfanylpropanoyl]amino]butanoyl]amino]-4-methylpentanoic acid;2,2,2-trifluoroacetic acid |
| Molecular Formula | C28H43F3N6O14S2 |
| Purity | ≥95% |
| InChI | InChI=1S/C26H42N6O12S2.C2HF3O2/c1-13(2)8-17(26(43)44)32-24(41)15(4-5-20(35)36)30-25(42)18(11-45)29-19(34)10-27-22(39)16(9-21(37)38)31-23(40)14(28-12-33)6-7-46-3;3-2(4,5)1(6)7/h12-18,45H,4-11H2,1-3H3,(H,27,39)(H,28,33)(H,29,34)(H,30,42)(H,31,40)(H,32,41)(H,35,36)(H,37,38)(H,43,44);(H,6,7)/t14-,15-,16-,17-,18-;/m0./s1 |
| InChIKey | CLBGNYFFUUHBLL-HGIJKBOGSA-N |
| SMILES | CC(C)CC(C(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C(CS)NC(=O)CNC(=O)C(CC(=O)O)NC(=O)C(CCSC)NC=O.C(=O)(C(F)(F)F)O |
| Reference | [1]. Säfholm A, et al. The Wnt-5a-derived hexapeptide Foxy-5 inhibits breast cancer metastasis in vivo by targeting cell motility. Clin Cancer Res. 2008 Oct 15;14(20):6556-63. [2]. Osman J, et al. The WNT5A Agonist Foxy5 Reduces the Number of Colonic Cancer Stem Cells in a Xenograft Mouse Model of Human Colonic Cancer. Anticancer Res. 2019 Apr;39(4):1719-1728. [3]. Canesin G, et al. Treatment with the WNT5A-mimicking peptide Foxy-5 effectively reduces the metastatic spread of WNT5A-low prostate cancer cells in an orthotopic mouse model. PLoS One. 2017 Sep 8;12(9):e0184418. |
